Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma have?
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma has 1,781 citations in the OpenAlex counts ScholarIQ stores.
When was Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma published?
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma has 2021 year in the ScholarIQ index.
What is the open-access status of Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma?
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma has bronze oa status in the ScholarIQ index.
What is the DOI of Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma?
The DOI for Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma is on the source record.
What is the PMID of Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma?
The PMID for Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma is on the source record.
What is the OpenAlex record for Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma?
The OpenAlex for Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma is on the source record.